Cargando…
Molecular characterization of feline immune checkpoint molecules and establishment of PD-L1 immunohistochemistry for feline tumors
Spontaneous tumors are a major cause of death in cats. Treatment of human tumors has progressed dramatically in the past decade, partly due to the success of immunotherapies using immune checkpoint inhibitors, such as anti-programmed death 1 (PD-1) and anti-PD-ligand 1 (PD-L1) antibodies. However, l...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9879432/ https://www.ncbi.nlm.nih.gov/pubmed/36701405 http://dx.doi.org/10.1371/journal.pone.0281143 |
_version_ | 1784878686941478912 |
---|---|
author | Maekawa, Naoya Konnai, Satoru Asano, Yumie Otsuka, Takumi Aoki, Eri Takeuchi, Hiroto Kato, Yukinari Kaneko, Mika K. Yamada, Shinji Kagawa, Yumiko Nishimura, Maki Takagi, Satoshi Deguchi, Tatsuya Ohta, Hiroshi Nakagawa, Takayuki Suzuki, Yasuhiko Okagawa, Tomohiro Murata, Shiro Ohashi, Kazuhiko |
author_facet | Maekawa, Naoya Konnai, Satoru Asano, Yumie Otsuka, Takumi Aoki, Eri Takeuchi, Hiroto Kato, Yukinari Kaneko, Mika K. Yamada, Shinji Kagawa, Yumiko Nishimura, Maki Takagi, Satoshi Deguchi, Tatsuya Ohta, Hiroshi Nakagawa, Takayuki Suzuki, Yasuhiko Okagawa, Tomohiro Murata, Shiro Ohashi, Kazuhiko |
author_sort | Maekawa, Naoya |
collection | PubMed |
description | Spontaneous tumors are a major cause of death in cats. Treatment of human tumors has progressed dramatically in the past decade, partly due to the success of immunotherapies using immune checkpoint inhibitors, such as anti-programmed death 1 (PD-1) and anti-PD-ligand 1 (PD-L1) antibodies. However, little is known about the PD-1 pathway and its association with tumor disease in cats. This study investigated the applicability of anti-PD-1/PD-L1 therapy in feline tumors. We first determined the complete coding sequence of feline PD-L1 and PD-L2, and found that the deduced amino acid sequences of feline PD-L1/PD-L2 share high sequence identities (66–83%) with orthologs in other mammalian species. We prepared recombinant feline PD-1, PD-L1, and PD-L2 proteins and confirmed receptor–ligand binding between PD-1 and PD-L1/PD-L2 using flow cytometry. Next, we established an anti-feline PD-L1 monoclonal antibody (clone CL1Mab-7) to analyze the expression of PD-L1. Flow cytometry using CL1Mab-7 revealed the cell surface expression of PD-L1 in a feline macrophage (Fcwf-4) and five mammary adenocarcinoma cell lines (FKNp, FMCm, FYMp, FONp, and FONm), and showed that PD-L1 expression was upregulated by interferon-γ stimulation. Finally, immunohistochemistry using CL1Mab-7 also showed PD-L1 expression in feline squamous cell carcinoma (5/5, 100%), mammary adenocarcinoma (4/5, 80%), fibrosarcoma (5/5, 100%), and renal cell carcinoma (2/2, 100%) tissues. Our results strongly encourage further investigations of the PD-1/PD-L1 pathway as a potential therapeutic target for feline tumors. |
format | Online Article Text |
id | pubmed-9879432 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-98794322023-01-27 Molecular characterization of feline immune checkpoint molecules and establishment of PD-L1 immunohistochemistry for feline tumors Maekawa, Naoya Konnai, Satoru Asano, Yumie Otsuka, Takumi Aoki, Eri Takeuchi, Hiroto Kato, Yukinari Kaneko, Mika K. Yamada, Shinji Kagawa, Yumiko Nishimura, Maki Takagi, Satoshi Deguchi, Tatsuya Ohta, Hiroshi Nakagawa, Takayuki Suzuki, Yasuhiko Okagawa, Tomohiro Murata, Shiro Ohashi, Kazuhiko PLoS One Research Article Spontaneous tumors are a major cause of death in cats. Treatment of human tumors has progressed dramatically in the past decade, partly due to the success of immunotherapies using immune checkpoint inhibitors, such as anti-programmed death 1 (PD-1) and anti-PD-ligand 1 (PD-L1) antibodies. However, little is known about the PD-1 pathway and its association with tumor disease in cats. This study investigated the applicability of anti-PD-1/PD-L1 therapy in feline tumors. We first determined the complete coding sequence of feline PD-L1 and PD-L2, and found that the deduced amino acid sequences of feline PD-L1/PD-L2 share high sequence identities (66–83%) with orthologs in other mammalian species. We prepared recombinant feline PD-1, PD-L1, and PD-L2 proteins and confirmed receptor–ligand binding between PD-1 and PD-L1/PD-L2 using flow cytometry. Next, we established an anti-feline PD-L1 monoclonal antibody (clone CL1Mab-7) to analyze the expression of PD-L1. Flow cytometry using CL1Mab-7 revealed the cell surface expression of PD-L1 in a feline macrophage (Fcwf-4) and five mammary adenocarcinoma cell lines (FKNp, FMCm, FYMp, FONp, and FONm), and showed that PD-L1 expression was upregulated by interferon-γ stimulation. Finally, immunohistochemistry using CL1Mab-7 also showed PD-L1 expression in feline squamous cell carcinoma (5/5, 100%), mammary adenocarcinoma (4/5, 80%), fibrosarcoma (5/5, 100%), and renal cell carcinoma (2/2, 100%) tissues. Our results strongly encourage further investigations of the PD-1/PD-L1 pathway as a potential therapeutic target for feline tumors. Public Library of Science 2023-01-26 /pmc/articles/PMC9879432/ /pubmed/36701405 http://dx.doi.org/10.1371/journal.pone.0281143 Text en © 2023 Maekawa et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Maekawa, Naoya Konnai, Satoru Asano, Yumie Otsuka, Takumi Aoki, Eri Takeuchi, Hiroto Kato, Yukinari Kaneko, Mika K. Yamada, Shinji Kagawa, Yumiko Nishimura, Maki Takagi, Satoshi Deguchi, Tatsuya Ohta, Hiroshi Nakagawa, Takayuki Suzuki, Yasuhiko Okagawa, Tomohiro Murata, Shiro Ohashi, Kazuhiko Molecular characterization of feline immune checkpoint molecules and establishment of PD-L1 immunohistochemistry for feline tumors |
title | Molecular characterization of feline immune checkpoint molecules and establishment of PD-L1 immunohistochemistry for feline tumors |
title_full | Molecular characterization of feline immune checkpoint molecules and establishment of PD-L1 immunohistochemistry for feline tumors |
title_fullStr | Molecular characterization of feline immune checkpoint molecules and establishment of PD-L1 immunohistochemistry for feline tumors |
title_full_unstemmed | Molecular characterization of feline immune checkpoint molecules and establishment of PD-L1 immunohistochemistry for feline tumors |
title_short | Molecular characterization of feline immune checkpoint molecules and establishment of PD-L1 immunohistochemistry for feline tumors |
title_sort | molecular characterization of feline immune checkpoint molecules and establishment of pd-l1 immunohistochemistry for feline tumors |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9879432/ https://www.ncbi.nlm.nih.gov/pubmed/36701405 http://dx.doi.org/10.1371/journal.pone.0281143 |
work_keys_str_mv | AT maekawanaoya molecularcharacterizationoffelineimmunecheckpointmoleculesandestablishmentofpdl1immunohistochemistryforfelinetumors AT konnaisatoru molecularcharacterizationoffelineimmunecheckpointmoleculesandestablishmentofpdl1immunohistochemistryforfelinetumors AT asanoyumie molecularcharacterizationoffelineimmunecheckpointmoleculesandestablishmentofpdl1immunohistochemistryforfelinetumors AT otsukatakumi molecularcharacterizationoffelineimmunecheckpointmoleculesandestablishmentofpdl1immunohistochemistryforfelinetumors AT aokieri molecularcharacterizationoffelineimmunecheckpointmoleculesandestablishmentofpdl1immunohistochemistryforfelinetumors AT takeuchihiroto molecularcharacterizationoffelineimmunecheckpointmoleculesandestablishmentofpdl1immunohistochemistryforfelinetumors AT katoyukinari molecularcharacterizationoffelineimmunecheckpointmoleculesandestablishmentofpdl1immunohistochemistryforfelinetumors AT kanekomikak molecularcharacterizationoffelineimmunecheckpointmoleculesandestablishmentofpdl1immunohistochemistryforfelinetumors AT yamadashinji molecularcharacterizationoffelineimmunecheckpointmoleculesandestablishmentofpdl1immunohistochemistryforfelinetumors AT kagawayumiko molecularcharacterizationoffelineimmunecheckpointmoleculesandestablishmentofpdl1immunohistochemistryforfelinetumors AT nishimuramaki molecularcharacterizationoffelineimmunecheckpointmoleculesandestablishmentofpdl1immunohistochemistryforfelinetumors AT takagisatoshi molecularcharacterizationoffelineimmunecheckpointmoleculesandestablishmentofpdl1immunohistochemistryforfelinetumors AT deguchitatsuya molecularcharacterizationoffelineimmunecheckpointmoleculesandestablishmentofpdl1immunohistochemistryforfelinetumors AT ohtahiroshi molecularcharacterizationoffelineimmunecheckpointmoleculesandestablishmentofpdl1immunohistochemistryforfelinetumors AT nakagawatakayuki molecularcharacterizationoffelineimmunecheckpointmoleculesandestablishmentofpdl1immunohistochemistryforfelinetumors AT suzukiyasuhiko molecularcharacterizationoffelineimmunecheckpointmoleculesandestablishmentofpdl1immunohistochemistryforfelinetumors AT okagawatomohiro molecularcharacterizationoffelineimmunecheckpointmoleculesandestablishmentofpdl1immunohistochemistryforfelinetumors AT muratashiro molecularcharacterizationoffelineimmunecheckpointmoleculesandestablishmentofpdl1immunohistochemistryforfelinetumors AT ohashikazuhiko molecularcharacterizationoffelineimmunecheckpointmoleculesandestablishmentofpdl1immunohistochemistryforfelinetumors |